A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib Click for Study A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib Sponsor: Amgen Protocol Number: IST-CAR-2014-100701 Start Date: 11/21/2014 Active, estimate end date – end of November 2020